Michael Racine, MD
Pediatric Endocrinology · Roseburg, ORNPI 1144287848
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,275 of the $2,011 with a category attached, or 63.4%. 11 manufacturers reported payments, led by Medtronic at 53.5% of the total. Reporting peaked in 2019 at $1,179 and has fallen 85.4% since, to $173 in 2025.
Across 132 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$489
- Tandem Diabetes Care, Inc.$133
- Recordati_rare_diseases_inc.$102
- Johnson & Johnson$65
- Insulet Corporation$44
- plus $103 from 5 others
What the payments were for
- Travel & lodging$72436%
- Food & beverage$1,27563%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 37 | $1,075 |
| Novo Nordisk | 76 | $489 |
| Tandem Diabetes Care, Inc. | 6 | $133 |
| Recordati_rare_diseases_inc. | 2 | $102 |
| Johnson & Johnson | 3 | $65 |
| Insulet Corporation | 2 | $44 |
| BETA Bionics, Inc. | 2 | $30 |
| AstraZeneca | 1 | $23 |
| Senseonics, Incorporated | 1 | $21 |
| AbbVie | 1 | $16 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric endocrinology providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 261 | $255,506 |
| OzempicSemaglutide | 229 | $226,575 |
| JardianceEmpagliflozin | 253 | $203,359 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 170 | $86,738 |
| FarxigaDapagliflozin Propanediol | 89 | $82,205 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $53,291 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $42,889 |
| RybelsusSemaglutide | 27 | $42,115 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $41,745 |
| JanuviaSitagliptin Phosphate | 40 | $36,553 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $28,352 |
| ProliaDenosumab | 17 | $28,188 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $26,997 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $24,969 |
| MounjaroTirzepatide | 23 | $23,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $12 | $288,724312 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $489 | $274,147292 claims |
| AstraZenecaFarxiga | $23 | $82,20589 claims |
| Johnson & JohnsonInvokana | $65 | $12,35816 claims |
| AbbVieSynthroid | $16 | $3,33248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric endocrinology providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other pediatric endocrinology in Roseburg
- Bruce BostonPortland$32K
- Daniel MarksPortland$28K
- Maya HunterPortland$1K
- Stephen LafranchiPortland$1K
- Angela Elaine LennonPortland$890
- Kathryn WoodsPortland$833
- Radhika PurushothamanPortland$765
- Marcie Drury BrownPortland$217
- Charlene LaiPortland$190
- David SnyderPortland$51
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.